#FierceMadness: BMS’ Zeposia, Gilead’s Trodelvy and Lilly’s Retevmo advance to Sweet 16 as Horizon’s Tepezza wins bignews2022-03-14T09:00:27+00:00March 14th, 2022|Fierce Pharma|
#FierceMadness: BioMarin’s Voxzogo and Merck’s Ebanga make the Elite 8. Now vote for your Final 4news2022-03-14T09:00:27+00:00March 14th, 2022|Fierce Pharma|
#FierceMadness: BioMarin, AstraZeneca, Horizon and ChemoCentryx in the Final 4 showdownnews2022-03-14T09:00:27+00:00March 14th, 2022|Fierce Pharma|
#FierceMadness: BioMarin’s Voxzogo battles ChemoCentryx’ Tavneos for the championshipnews2022-03-14T09:00:27+00:00March 14th, 2022|Fierce Pharma|
ChemoCentryx’ Tavneos trounces BioMarin’s Voxzogo to win #FierceMadness drug name tournament championshipnews2022-03-14T09:00:27+00:00March 14th, 2022|Fierce Pharma|
Chiesi study aims to quantify economic benefits of rare disease drugsnews2022-03-14T03:05:28+00:00March 14th, 2022|Fierce Pharma|
Stevanato’s growth spree rolls on with China plant purchase, plans for 270 jobsnews2022-03-11T16:08:12+00:00March 11th, 2022|Fierce Pharma|
BeiGene, Hutchmed, Zai Lab tagged for potential US delisting under SEC audit rules, with more Chinese biotechs likely to face scrutinynews2022-03-11T15:01:02+00:00March 11th, 2022|Fierce Pharma|
GlaxoSmithKline’s Shingrix campaign irks some in UK, but pharma adamant it broke no rulesnews2022-03-11T14:58:52+00:00March 11th, 2022|Fierce Pharma|
Amid inflation spike, execs at J&J, Bayer, GSK and more talk higher costs—and what it means for profitsnews2022-03-11T14:37:08+00:00March 11th, 2022|Fierce Pharma|
